Trial Profile
OLP-1002 - A First-in-human, Double-blind, Placebo-controlled, Single and Multiple Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs OLP 1002 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- Sponsors OliPass
- 03 Nov 2020 Status changed from recruiting to completed.
- 12 May 2020 Planned End Date changed from 1 Mar 2020 to 1 Oct 2020.
- 12 May 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2020.